biology of incretins glp 1 and gip INCRETIN Incretins Explained | GLP-1 &
Description
Faculty of Medicine, McGill University, Montreal, QC, Canada
In a 52-week trial of pediatric insulin-experienced type 1 diabetes patients, 84.1% of patients who received TRESIBA were positive at baseline for anti-insulin degludec antibodies and 5.8% of patients developed anti-insulin degludec antibodies at least once during the trial
Availability : Brand-name GLP-1 medications may be harder to come by due to supply shortages, whereas compounded versions are often easier to access
@rhiannaBjourno
doi: 10.1038/sj.ijo.0802206 100 KastinA
